Abiraterone acetate

Johnson & Johnson Reports Q4 and Full-Year 2023 Results

Retrieved on: 
Tuesday, January 23, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Growth, Contact, Ustekinumab, Esketamine, General surgery, Infliximab, Abiraterone acetate, Press release, Acquisition, COVID-19, Medtech, Johnson & Johnson, Abiomed, Daratumumab, Security (finance), News, Pharmaceutical industry

Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency.

Key Points: 
  • Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency.
  • Innovative Medicine worldwide operational sales, excluding the COVID-19 Vaccine, grew 7.2%*.
  • Notable New Announcements in the Quarter:
    The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.
  • Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Human medicines European public assessment report (EPAR): Zytiga, abiraterone, Date of authorisation: 05/09/2011, Revision: 27, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Prednisolone, European Commission, Liver, Agency, Survival, CYP17, INN, Woman, Docetaxel, Fracture, ATC, Male, Hormone, Hypersensitivity, International, Cough, Man, European, Prednisone, Disease, Language, Prostate cancer, Cerebral edema, Eating, Castration, Cancer, Urinary tract infection, Neoplasm, Testosterone, Prostate, Abiraterone acetate, European Medicines Agency, Food, Tablet, Growth, Select, Anatomy, Medicine, IIA, Hypokalemia

Human medicines European public assessment report (EPAR): Zytiga, abiraterone, Date of authorisation: 05/09/2011, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zytiga, abiraterone, Date of authorisation: 05/09/2011, Revision: 27, Status: Authorised

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

Retrieved on: 
Wednesday, December 20, 2023
GT0918, Niraparib, Phase, Ipsen, CRPC, Prognosis, Daiichi Sankyo, PSMA, BRCA, FDA, Spacecraft, Gesellschaft mit beschränkter Haftung, DNA, EU4, Cancer, Novartis, ICIS, Abiraterone acetate, Ageing, Urination, PSA, Metastasis, CYP17, Survival rate, Pain, Prevalence, Bristol Myers Squibb, Prednisone, Janssen Pharmaceuticals, Testosterone, PARP, Rucaparib, Urine, Neoplasm, Urethra, Johnson & Johnson, AstraZeneca, Docetaxel, STEAP1, Bone pain, AMG, Blood, ADT, LAS, Patient, Prostate-specific antigen, Astellas Pharma, HRR, Amgen, Prostate cancer, Swelling, Eli Lilly and Company, Hypoesthesia, Science, Growth, Merck & Co., Pressure, Pharmaceutical industry

LAS VEGAS, Dec. 20, 2023 /PRNewswire/ -- DelveInsight's Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, mCRPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the total metastatic castration-resistant prostate cancer market size in the 7MM was estimated to be nearly USD 6.4 billion in 2022, which is expected to show positive growth by 2032.
  • As per DelveInsight estimates, in 2022, total diagnosed prevalent cases of mCRPC were around 127K in the 7MM.
  • However, mCRPC remains a lethal diagnosis and more effective therapeutic approaches against mCRPC are necessary to improve clinical outcomes further.
  • The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer.

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

Retrieved on: 
Wednesday, December 20, 2023
GT0918, Niraparib, Phase, Ipsen, CRPC, Prognosis, Daiichi Sankyo, PSMA, BRCA, FDA, Spacecraft, Gesellschaft mit beschränkter Haftung, DNA, EU4, Cancer, Novartis, ICIS, Abiraterone acetate, Ageing, Urination, PSA, Metastasis, CYP17, Survival rate, Pain, Prevalence, Bristol Myers Squibb, Prednisone, Janssen Pharmaceuticals, Testosterone, PARP, Rucaparib, Urine, Neoplasm, Urethra, Johnson & Johnson, AstraZeneca, Docetaxel, STEAP1, Bone pain, AMG, Blood, ADT, LAS, Patient, Prostate-specific antigen, Astellas Pharma, HRR, Amgen, Prostate cancer, Swelling, Eli Lilly and Company, Hypoesthesia, Science, Growth, Merck & Co., Pressure, Pharmaceutical industry

LAS VEGAS, Dec. 20, 2023 /PRNewswire/ -- DelveInsight's Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, mCRPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the total metastatic castration-resistant prostate cancer market size in the 7MM was estimated to be nearly USD 6.4 billion in 2022, which is expected to show positive growth by 2032.
  • As per DelveInsight estimates, in 2022, total diagnosed prevalent cases of mCRPC were around 127K in the 7MM.
  • However, mCRPC remains a lethal diagnosis and more effective therapeutic approaches against mCRPC are necessary to improve clinical outcomes further.
  • The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer.

Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

Retrieved on: 
Wednesday, October 25, 2023
Trial of the century, Harvard Medical School, Brigham and Women's Hospital, Therapy, Clinical Cancer Research, Prostate cancer, MD, Dana–Farber Cancer Institute, Doctor of Philosophy, HIV disease progression rates, Journal, Internal medicine, Estate (law), Duke University School of Medicine, Abiraterone acetate, Metastasis, SAN, Oncology, Biochemistry, Massachusetts Institute of Technology, Journal of Clinical Oncology, AR, Canisius College, Patient, Hospital, SAB, Massachusetts Institute of Technology School of Engineering, Prostate, The New England Journal of Medicine, Pharmaceutical industry, Medicine, Lancet

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB).

Key Points: 
  • SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB).
  • “We wholeheartedly welcome Dr. Smith to Oncternal’s Prostate Cancer Scientific Advisory Board,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.
  • He has published extensively on the treatment and prevention of bone metastases, prostate cancer survivorship, and novel androgen receptor pathway inhibitors.
  • He completed a fellowship in Medical Oncology at Dana Farber Cancer Institute and a postdoctoral fellowship at Massachusetts Institute of Technology.

Johnson & Johnson Reports Q3 2023 Results

Retrieved on: 
Tuesday, October 17, 2023
Oncology, Retail, Health, Other Retail, Clinical Trials, Biotechnology, General surgery, COVID-19, Acquisition, Ustekinumab, Abiomed, Pulmonary hypertension, Johnson & Johnson, Growth, Esketamine, Daratumumab, Contact, Infliximab, Innovative Medicines Canada, Medtech, News, Abiraterone acetate, Security (finance), Pharmaceutical industry, Neuroscience, Immunology, Vision

Third Quarter 2023 Segment Commentary:

Key Points: 
  • Third Quarter 2023 Segment Commentary:
    Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency.
  • Excluding the COVID-19 Vaccine, operational sales grew 8.2%*.
  • Notable New Announcements in the Quarter:
    The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.
  • Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson.

Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO

Retrieved on: 
Monday, October 16, 2023
Congress, Cohort, HIV disease progression rates, Erdafitinib, Lung cancer, Doctor of Philosophy, Amivantamab, Abstract, Pembrolizumab, Research, NSCLC, PAPILLON, Therapy, Janssen, EGFR, Johnson & Johnson, Janssen Pharmaceuticals, Safety, Disease, Pemetrexed, Oncology, ESMO, Prednisone, Clinical Genitourinary Cancer, BRCA, HRR, Bladder cancer, MUC, European Society for Medical Oncology, Pancreatic cancer, Prostate cancer, Abiraterone acetate, Progression-free survival, FGFR, Patient, Medical imaging, Pharmaceutical industry, Vaccine

RARITAN, N.J., Oct. 16, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that nine oral presentations from the Company's robust solid tumor portfolio and pipeline, with three highlighted in Presidential Symposium sessions, will be featured at the European Society for Medical Oncology (ESMO) 2023 Congress. In total, 19 studies (17 company-sponsored abstracts and two investigator-initiated studies), including seven late-breaking abstracts, will feature new data and updates in lung cancer, bladder cancer, and prostate cancer, highlighting Janssen's pioneering efforts to transform the treatment of solid tumors.

Key Points: 
  • "The data and results premiering at this year's ESMO represent our determination to advance oncology science and set new innovation standards in the treatment of solid tumor malignancies," said Peter Lebowitz, M.D., PhD, Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC.
  • "The evolution of targeted therapeutics in oncology presents a promising path forward to bring the very latest innovations to patients.
  • Data in bladder cancer underscore Janssen's ambition to advance new therapies and approaches to address unmet treatment needs.
  • Building on a legacy in the treatment of prostate cancer, data at ESMO highlight precision-driven and patient-centric strategies across the disease continuum.

AKEEGA™ (niraparib and abiraterone acetate) Now Available from Onco360

Retrieved on: 
Tuesday, October 3, 2023
General Health, Health, Pharmaceutical, Clinical Trials, Oncology, Janssen Pharmaceuticals, Disease, Journal of Oncology Pharmacy Practice, PharMerica, HRR, ADP, Abiraterone acetate, CI, National Cancer Institute, Janssen, ADT, Toxicity, Pharmacy, Prednisone, Death, BRCA2, Hospital, Specialty pharmacy, HIV disease progression rates, Patient, Risk, Testosterone, SEER, Johnson & Johnson, Gonadotropin-releasing hormone, BRCA, FDA, PARP, Orchiectomy, Phase, CYP17, Prostate cancer, Pharmaceutical industry, Epidemiology

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by The Janssen Pharmaceutical Companies of Johnson & Johnson for AKEEGA™ (niraparib and abiraterone acetate).

Key Points: 
  • Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by The Janssen Pharmaceutical Companies of Johnson & Johnson for AKEEGA™ (niraparib and abiraterone acetate).
  • Patients should be selected for therapy based on an FDA-approved test for AKEEGA.
  • Patients taking AKEEGA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
  • “Onco360 is thankful for the opportunity to partner with the team at Janssen and become a specialty pharmacy provider for AKEEGA,” said Benito Fernandez, Chief Commercial Officer.